Burning Rock Biotech Limited Capitalized Contract Cost, Impairment Loss
Burning Rock Biotech Limited (BNR) reported Capitalized Contract Cost, Impairment Loss of CNY 65.65 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CapitalizedContractCostImpairmentLoss · last filed 2026-04-28
CNY
| Period end | Capitalized Contract Cost, Impairment Loss 12 month | Capitalized Contract Cost, Impairment Loss 12 month as first filed |
|---|---|---|
| 2025-12-31 | 65.65M CNY 20-F · filed 2026-04-28 | |
| 2024-12-31 | 61.86M CNY 20-F · filed 2026-04-28 | |
| 2023-12-31 | 58.79M CNY 20-F · filed 2025-04-29 | 23.02M CNY 20-F · filed 2024-04-29 |
| 2022-12-31 | 35.77M CNY 20-F · filed 2023-04-20 | |
| 2021-12-31 | 14.48M CNY 20-F · filed 2023-04-20 | |
| 2020-12-31 | 3.50M CNY 20-F · filed 2023-04-20 | |
| 2019-12-31 | 0.00 CNY 20-F · filed 2022-04-29 | |
| 2018-12-31 | 0.00 CNY 20-F · filed 2021-03-23 |
USD
| Period end | Capitalized Contract Cost, Impairment Loss 12 month |
|---|---|
| 2025-12-31 | $9.39M 20-F · filed 2026-04-28 |
| 2024-12-31 | $8.47M 20-F · filed 2025-04-29 |
| 2023-12-31 | $3.24M 20-F · filed 2024-04-29 |
| 2022-12-31 | $5.19M 20-F · filed 2023-04-20 |
| 2021-12-31 | $2.27M 20-F · filed 2022-04-29 |
| 2020-12-31 | $536.00K 20-F · filed 2021-03-23 |